New positive long-term data for JAK inhibitor Olumiant in RA
Olumiant maintained a consistent safety profile in a long-term analysis of patients with rheumatoid arthritis
Read More
Author: Lucy Parsons
Updated guidelines for managing long-term effects of COVID-19 published
New guidelines from NICE, SIGN and the RCGP includes an update to original list of common symptoms
Read More
Valneva receives EU deal for COVID jab, and seeks apology from UK
Decision follows the UK government’s termination of their deal with Valneva in September
Read More
University of Oxford begins human trials of Ebola vaccine
ChAdOxl biEBOV is being tested for safety and immunogenicity, and may protect against multiple species of the virus
Read More
‘Ground-breaking’ research on inflammatory disease treatment set to be commercialised
The new research by Heriot-Watt University has identified a way of targeting an enzyme called EPAC1
Read More- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
